TuHURA Biosciences, Inc.
6 clinical trials · Sponsor
◉ Watch TuHURA Biosciences, Inc.
| Record | Firm | Date |
|---|---|---|
| Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma (NCT06947928) | TuHURA Biosciences, Inc. | 2025-12-11 |
| IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) (NCT06940440) | TuHURA Biosciences, Inc. | 2025-10-01 |
| Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers (NCT04160065) | TuHURA Biosciences, Inc. | 2020-03-03 |
| pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma (NCT03655756) | TuHURA Biosciences, Inc. | 2018-11-05 |
Track TuHURA Biosciences, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.